Tevogen Bio Holdings Inc (TVGN) Stock Price, Quote & News

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pat...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 838 6434

Website: tevogen.com

Address:

15 Independence Boulevard, Suite #210, Warren, United States

Praxis2 Jun. 4 at 10:24 PM

$TVGN any dilution open?

0 · Reply

Thewolf76 Jun. 4 at 8:37 PM

$TVGN “TVGN may be one of the most undervalued micro-cap stocks on Nasdaq today. The company is currently valued at only around $35–40 million, yet insiders control approximately 74% of the outstanding shares and the tradable float is extremely small. In other words, very few shares are actually available on the open market. Over the past few months, the company has: * Raised private capital at $8 per share; * Initiated acquisition efforts that could potentially generate up to approximately $100 million in combined annual revenue; * Continued advancing its PredictCell AI platform; * Expanded its Tevogen Generics strategy; * Maintained strong insider ownership without significant insider selling.

1 · Reply

Thewolf76 Jun. 4 at 8:34 PM

$TVGN buy buy buy

0 · Reply

Thewolf76 Jun. 4 at 7:47 PM

$TVGN 80% of the shares are in the hands of institutional investors and the owner. Do you have any idea what that means? Everything will explode overnight. We'll be back to $100 in no time. Get in before it's too late and you'll be screwed.

0 · Reply

Thewolf76 Jun. 4 at 7:44 PM

$TVGN 🚀🚀🚀🪙

0 · Reply

Thewolf76 Jun. 4 at 7:43 PM

$TVGN this title is ready for takeoff

0 · Reply

MrAlientrader Jun. 4 at 7:28 PM

$TVGN short fee 56% on IB means people willing to pay high fee to borrow shares and short. A big buyer then shorts will be screwed

1 · Reply

MrAlientrader Jun. 4 at 7:02 PM

$TVGN short interest all time high today, interesting

0 · Reply

Thewolf76 Jun. 4 at 6:15 PM

$TVGN We will return to $100 very soon, the float is so low that just one small piece of news out of the many that will come out is enough

0 · Reply

supplySHOCK Jun. 4 at 10:11 AM

$SPRC $PW $BARK $TVGN shirt

0 · Reply

Tevogen advances strategic acquisition initiatives

May 28, 2026, 12:30 PM EDT - 7 days ago

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 21, 2026, 12:15 PM EDT - 14 days ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 18, 2026, 12:15 PM EDT - 17 days ago

Letter to Shareholders from CEO Dr. Ryan Saadi

2026-05-12T18:10:14.000Z - 23 days ago

Tevogen Bio Holdings Inc trading halted, volatility trading pause

2026-05-12T18:07:55.000Z - 23 days ago

Tevogen Bio Holdings Inc trading resumes

May 12, 2026, 11:45 AM EDT - 23 days ago

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Apr 27, 2026, 11:50 AM EDT - 5 weeks ago

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Mar 26, 2026, 12:45 PM EDT - 2 months ago

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

2026-03-25T18:25:30.000Z - 2 months ago

Tevogen regains compliance with Nasdaq minimum bid price requirement

Mar 25, 2026, 2:20 PM EDT - 2 months ago

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 18, 2026, 12:22 PM EDT - 2 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Mar 13, 2026, 2:45 PM EDT - 2 months ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

2026-03-13T16:40:31.000Z - 2 months ago

Tevogen reports performance advancements for Tevogen.AI platform

Mar 13, 2026, 12:30 PM EDT - 2 months ago

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Mar 11, 2026, 3:15 PM EDT - 3 months ago

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

2026-03-09T11:51:22.000Z - 3 months ago

Tevogen appoints interim leaders across core business verticals

Mar 9, 2026, 7:45 AM EDT - 3 months ago

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

2026-03-06T20:45:38.000Z - 3 months ago

Tevogen CEO says ‘actively evaluating potential acquisitions’

2026-03-06T15:20:39.000Z - 3 months ago

Tevogen Bio Holdings Inc trading resumes

2026-03-06T15:15:32.000Z - 3 months ago

Tevogen Bio Holdings Inc trading halted, volatility trading pause

2026-03-06T00:51:12.000Z - 3 months ago

Tevogen Bio Holdings Inc trading halted, news pending

2026-03-05T20:00:17.000Z - 3 months ago

Tevogen signs LOI to evaluate potential acquisition of Apozeal Pharmaceutical

Mar 5, 2026, 2:50 PM EST - 3 months ago

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

2026-03-04T14:23:36.000Z - 3 months ago

Tevogen downgraded to Hold from Buy at D. Boral Capital

2026-03-04T13:13:07.000Z - 3 months ago

Tevogen announces 50-for-1 reverse stock split

Mar 4, 2026, 8:00 AM EST - 3 months ago

Tevogen Announces Reverse Stock Split

2026-02-27T19:25:58.000Z - 3 months ago

Tevogen signs LoI to evaluate acquisition of contract research organization

Feb 27, 2026, 2:20 PM EST - 3 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

Feb 26, 2026, 4:22 PM EST - 3 months ago

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

2026-02-26T14:39:08.000Z - 3 months ago

Tevogen signs non-binding LOI to evaluate acquisition of Sciometrix

Feb 26, 2026, 9:20 AM EST - 3 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

2026-01-30T20:05:31.000Z - 4 months ago

Tevogen to evaluate potential one-time special cash dividend

Jan 30, 2026, 3:00 PM EST - 4 months ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Jan 29, 2026, 2:45 PM EST - 4 months ago

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

2026-01-12T14:11:33.000Z - 5 months ago

Tevogen reports scientific, operational milestones achieved in 2025

Jan 12, 2026, 9:00 AM EST - 5 months ago

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Dec 22, 2025, 12:40 PM EST - 5 months ago

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Dec 19, 2025, 11:10 AM EST - 5 months ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Dec 11, 2025, 3:15 PM EST - 6 months ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Dec 9, 2025, 2:20 PM EST - 6 months ago

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Dec 8, 2025, 2:50 PM EST - 6 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Nov 14, 2025, 2:32 PM EST - 7 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

2025-11-05T20:25:58.000Z - 7 months ago

Tevogen announces clinical milestone in evolution of ExacTcell platform

Nov 5, 2025, 3:20 PM EST - 7 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Nov 3, 2025, 2:45 PM EST - 7 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Oct 29, 2025, 12:35 PM EDT - 7 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

2025-10-15T19:55:53.000Z - 8 months ago

Tevogen provides update on TVGN 489 amid Long COVID patient interest

Oct 15, 2025, 3:50 PM EDT - 8 months ago

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 23, 2025, 8:30 AM EDT - 9 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 19, 2025, 3:40 PM EDT - 9 months ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 10, 2025, 11:59 AM EDT - 9 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 9, 2025, 3:15 PM EDT - 9 months ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 8, 2025, 9:27 AM EDT - 9 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 4, 2025, 3:48 PM EDT - 9 months ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 3, 2025, 4:15 PM EDT - 9 months ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Aug 27, 2025, 3:20 PM EDT - 10 months ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 26, 2025, 2:50 PM EDT - 10 months ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 25, 2025, 3:10 PM EDT - 10 months ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 22, 2025, 3:25 PM EDT - 10 months ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 19, 2025, 3:40 PM EDT - 10 months ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 12:10 PM EDT - 10 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 18, 2025, 5:50 PM EDT - 10 months ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:15 PM EDT - 10 months ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 14, 2025, 3:55 PM EDT - 10 months ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Aug 13, 2025, 3:53 PM EDT - 10 months ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 11, 2025, 3:45 PM EDT - 10 months ago

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Aug 11, 2025, 1:24 PM EDT - 10 months ago

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Praxis2 Jun. 4 at 10:24 PM

$TVGN any dilution open?

0 · Reply

Thewolf76 Jun. 4 at 8:37 PM

1 · Reply

Thewolf76 Jun. 4 at 8:34 PM

$TVGN buy buy buy

0 · Reply

Thewolf76 Jun. 4 at 7:47 PM

0 · Reply

Thewolf76 Jun. 4 at 7:44 PM

$TVGN 🚀🚀🚀🪙

0 · Reply

Thewolf76 Jun. 4 at 7:43 PM

$TVGN this title is ready for takeoff

0 · Reply

MrAlientrader Jun. 4 at 7:28 PM

$TVGN short fee 56% on IB means people willing to pay high fee to borrow shares and short. A big buyer then shorts will be screwed

1 · Reply

MrAlientrader Jun. 4 at 7:02 PM

$TVGN short interest all time high today, interesting

0 · Reply

Thewolf76 Jun. 4 at 6:15 PM

$TVGN We will return to $100 very soon, the float is so low that just one small piece of news out of the many that will come out is enough

0 · Reply

supplySHOCK Jun. 4 at 10:11 AM

$SPRC $PW $BARK $TVGN shirt

0 · Reply

supplySHOCK Jun. 3 at 9:26 PM

$TVGN $YYAI $TC $MXC charts

0 · Reply

Somerandomnoname Jun. 1 at 10:17 PM

$TVGN anything under $8 is a buy, like seriously. I was able to reenter a very small position today sub $8. Happy to do it also.

0 · Reply

NGCS May. 29 at 11:27 PM

Why am I holding $TVGN for the long tech run? Look at AI drug discovery validation: 🔹 $RXRX: $12B Roche alliance + Nvidia backing. 🔹 $SDGR: Recurrent software revenue from top 20 big pharma. 🔹 Exscientia: Massively partnered w/ Bristol Myers Squibb & Sanofi. Big Pharma pays billions for predictive AI that cuts lab trial-and-error. Tevogen.AI with Microsoft cloud infrastructure is next in line. 💎🔥 IMO Big players are accumulating because the AI biotech space is a gold rush. The tech is real: - Recursion ($RXRX) merged with Exscientia to dominate chemistry+biology, validated by massive Sanofi/BMS/Roche partnerships. - Schrödinger ($SDGR) proved software cash-flow is stable. - Tevogen.AI's PredicTcell is built on the same disruptive tech demand. When the first licensing deal drops, this shorts-heavy stock explodes. 📈👀 NFA

1 · Reply

The_Gambl3r May. 28 at 11:20 PM

$TVGN 👀👀

0 · Reply

Thewolf76 May. 28 at 6:48 PM

$TVGN 🚀🚀🚀🚀

0 · Reply

MrAlientrader May. 28 at 5:53 PM

$TVGN any price below $8 is a buy that is why the main investor paid 14% premium over the market price

0 · Reply

Thewolf76 May. 28 at 5:44 PM

$TVGN I won't start selling my 30,000 shares until $50, this is a gem ready to explode, small float, few shares outstanding, it will explode soon

0 · Reply

HidingGem May. 28 at 5:21 PM

$TVGN let's see

0 · Reply

focafoca99 May. 28 at 5:17 PM

$TVGN announces progress on strategic acquisition initiatives that could add roughly $100 million of annual revenue.

1 · Reply

HidingGem May. 28 at 5:11 PM

$TVGN watch list

0 · Reply

NGCS May. 28 at 3:57 PM

$TVGN ⁠ No dilution on common shares (8k on SEC), $2M fresh cash in the bank from insiders, and back above $8.00. The shorts are trapped again. This is HUGE for retail: they get the funding needed to close those LOIs WITHOUT diluting common sharesPatience will pay off big when the first LOI officially closes. Bullish! 🔥👀 #Biotech

0 · Reply

Thewolf76 May. 28 at 12:43 PM

$TVGN Here we can explode any day now and get back to at least $100.

0 · Reply

Market Cap	35.27M
Revenue (ttm)	0.00
Net Income (ttm)	-26.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.65

Volume	16,400
Avg Vol	29,590
Day's Range	N/A - N/A
Shares Out	4.16M
Stochastic %K	66%
Beta	0.14
Analysts	Hold
Price Target	$100.00